Slashdot Mirror
Patients Regain Sight After Groundbreaking Trial (bbc.com)
An anonymous reader quotes a report from the BBC: Doctors have taken a major step towards curing the most common form of blindness in the UK -- age-related macular degeneration. Douglas Waters, 86, could not see out of his right eye, but "I can now read the newspaper" with it, he says. He was one of two patients given pioneering stem cell therapy at Moorfields Eye Hospital in London. Cells from a human embryo were grown into a patch that was delicately inserted into the back of the eye.
The macula is the part of the eye that allows you to see straight ahead -- whether to recognize faces, watch TV or read a book. The macula is made up of rods and cones that sense light and behind those are a layer of nourishing cells called the retinal pigment epithelium. When this support layer fails, it causes macular degeneration and blindness. Doctors have devised a way of building a new retinal pigment epithelium and surgically implanting it into the eye. The technique, published in Nature Biotechnology, starts with embryonic stem cells. These are a special type of cell that can become any other in the human body. They are converted into the type of cell that makes up the retinal pigment epithelium and embedded into a scaffold to hold them in place. The living patch is only one layer of cells thick -- about 40 microns -- and 6mm long and 4mm wide. It is then placed underneath the rods and cones in the back of the eye. The operation takes up to two hours.
The macula is the part of the eye that allows you to see straight ahead -- whether to recognize faces, watch TV or read a book. The macula is made up of rods and cones that sense light and behind those are a layer of nourishing cells called the retinal pigment epithelium. When this support layer fails, it causes macular degeneration and blindness. Doctors have devised a way of building a new retinal pigment epithelium and surgically implanting it into the eye. The technique, published in Nature Biotechnology, starts with embryonic stem cells. These are a special type of cell that can become any other in the human body. They are converted into the type of cell that makes up the retinal pigment epithelium and embedded into a scaffold to hold them in place. The living patch is only one layer of cells thick -- about 40 microns -- and 6mm long and 4mm wide. It is then placed underneath the rods and cones in the back of the eye. The operation takes up to two hours.
I remember when stem cell therapy was first making the news and getting people excited. It's really nice to read when that sort of basic research pays off with applied medicine. It's seeing the sci-fi books come to you and makes the future look a little more bright.
The BBC article says both patients had wet AMD.
Only 10-15% of AMD are "wet". Also wet AMD often only affects one eye. Dry AMD usually affects both.
This is still great news, and hopefully there will be new breakthroughs on the dry side soon. AMD affects more than 10 million people just in America, roughly 3% of the population, and that is expected to grow with demographic changes, doubling by 2050 without new treatments. An effective treatment will make a huge difference to the quality of life of many people.